Table 2 Changes in glycemic parameters from baseline to 24 weeks of the trial
Characteristics | FDC of MSP (n = 109) | MS (n = 107) |
|---|---|---|
Glycosylated hemoglobin, HbA1c (%) | ||
Baseline, Mean (SD) | 9.21 (0.78) | 9.25 (0.78) |
End of the study at 24-week, Mean (SD) | 7.56 (0.96) | 7.86 (1.12) |
LS mean change from baseline (95% CI) | −1.64 (−1.83, − 1.45) | −1.32 (− 1.52, − 1.13) |
LS mean difference between the groups (95% CI) | − 0.32 (− 0.59, − 0.05) | |
P value | 0.0208* | |
Fasting plasma glucose, FPG (mg/dL) | ||
Baseline, Mean (SD) | 163.14 (45.05) | 160.80 (44.24) |
End of the study at 24-week, Mean (SD) | 129.70 (30.64) | 142.06 (38.76) |
LS mean change from baseline (95% CI) | −31.22 (−37.88, −24.56) | −17.94 (− 24.81, − 11.07) |
LS mean difference between the groups (95% CI) | − 13.28 (− 22.86, − 3.71) | |
P value | 0.0068* | |
Post prandial plasma glucose, PPG (mg/dL) | ||
Baseline, Mean (SD) | 234.21 (68.92) | 244.85 (70.07) |
End of the study at 24-week, Mean (SD) | 178.75 (48.44) | 198.84 (50.44) |
LS mean change from baseline (95% CI) | −57.20 (−66.54, −47.86) | −36.37 (−45.81, −26.93) |
LS mean difference between the groups (95% CI) | −20.83 (−34.11, − 7.55) | |
P value | 0.0023* | |
Bodyweight (kg) | ||
Baseline, Mean (SD) | 67.29 (12.96) | 65.43 (11.08) |
End of the study at 24-week, Mean (SD) | 67.27 (12.52) | 64.94 (10.42) |
LS mean change from baseline (95% CI) | 0.10 (−0.25, 0.45) | −0.34 (− 0.69, 0.02) |
LS mean difference between the groups (95% CI) | 0.44 (− 0.06, 0.94) | |
P value | 0.085 | |